Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00788125 · OUTCOME

Maximum Administered Dose of Dasatinib (Phase I)

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors · Source last updated 2023-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/m2 dose BID
Interval / dispersion
Not reported
Time frame
28 days after start of course 1

What was measured

This field captured the maximum dose of dasatinib administered.

Analysis population: Level -1: 25 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 1: 35 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 2: 50 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 3: 65 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 4: 85 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 5 (Dasatinib alone phase only): 110 mg/m\^2/dose BID PO. Sponsor withdrew support before a second level could be attempted.

Groups in this outcome

Period 1: 35 mg/m^2/Dose BID PO Dasatinib x 17 Days

35 mg/m\^2/dose BID PO Dasatinib x 17 days Ifosfamide, Carboplatin, Etoposide therapeutic conventional surgery radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Period 1: 35 mg/m^2/Dose BID PO Dasatinib x 17 Days7

Reported measurements

Source class 1
Values in mg/m2 dose BID · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Period 1: 35 mg/m^2/Dose BID PO Dasatinib x 17 Days35Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        35
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
This field captured the maximum dose of dasatinib administered.
groups
  1. description
    35 mg/m\^2/dose BID PO Dasatinib x 17 days Ifosfamide, Carboplatin, Etoposide therapeutic conventional surgery radiation therapy
    id
    OG000
    title
    Period 1: 35 mg/m^2/Dose BID PO Dasatinib x 17 Days
param Type
NUMBER
population Description
Level -1: 25 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 1: 35 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 2: 50 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 3: 65 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 4: 85 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 5 (Dasatinib alone phase only): 110 mg/m\^2/dose BID PO. Sponsor withdrew support before a second level could be attempted.
reporting Status
POSTED
time Frame
28 days after start of course 1
title
Maximum Administered Dose of Dasatinib (Phase I)
type
PRIMARY
unit Of Measure
mg/m2 dose BID

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice